Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care.
Lykke Midtbøll ØrnbjergKathrine RugbjergStylianos GeorgiadisSimon Horskjær RasmussenLennart JacobssonAnne Gitte LoftFlorenzo IannoneKaren M FagerliJiri VencovskyMaria Jose SantosBurkhard MöllerManuel Pombo-SuarezŽiga RotarBjorn GudbjornssonAyse CefleKari EklundCatalin CodreanuGareth T JonesMarleen G H van de SandeJohan Karlsson WallmanMarco SebastianiBrigitte MichelsenJakub ZávadaMichael John NissenCarlos Sánchez-PiedraMatija TomšičThorvardur Jon LoveHeikki RelasCorina MogosanMerete Lund HetlandMikkel ØstergaardPublished in: The Journal of rheumatology (2024)
In 12,262 biologic-naïve patients with PsA, 6 months of treatment with a TNFi reduced pain by approximately 50%. Marked differences in PRO remission rates across treatment courses, registries, disease duration, sex, and age at onset of disease were observed, emphasizing the potential influence of factors other than disease activity on PROs.
Keyphrases
- disease activity
- rheumatoid arthritis
- patient reported outcomes
- systemic lupus erythematosus
- rheumatoid arthritis patients
- ankylosing spondylitis
- prostate cancer
- healthcare
- chronic pain
- pain management
- juvenile idiopathic arthritis
- palliative care
- risk assessment
- spinal cord injury
- human health
- health insurance
- replacement therapy
- climate change